WallStreetZenWallStreetZen

AnalystsJack Allen
Jack Allen's Stock Forecasts

Sectors:
Industries:
Analyst Ranking
Bottom 1%
#4526 out of 4554 analysts
Average Return
-23.31%
Win Rate
37%11 out of 30
Risk vs Reward
Poor
Good

Jack Allen's 5 best and worst ratings

Name / TickerGain/LossEntry PriceExit PricePeriodRating
Arcellx IncACLX
+98.19%$29.30$58.07
2023-04-12 -
2024-04-12
Buy
Arcellx IncACLX
+87.26%$31.01$58.07
2023-04-13 -
2024-04-12
Buy
Renovacor IncRCOR
+82.86%$1.75$3.20
2022-09-12 -
2022-11-30
Buy
Voyager Therapeutics IncVYGR
+60.68%$3.84$6.17
2021-10-06 -
2022-10-06
Buy
Arcellx IncACLX
+51.77%$35.91$54.50
2023-08-14 -
2024-04-18
Buy

Jack Allen Analyst Color

Get additional color on Jack Allen's coverage of popular stocks

Jack Allen's Stock Coverage

Name / TickerNo. RatingsRatingPrice TargetUpside/DownsideActionDate
Arcellx IncACLX
4Buy$77.00+41.28%Maintains
2 months ago
Instil Bio IncTIL
6Buy$54.00+418.73%Reiterates
3 months ago
Bluebird Bio IncBLUE
2Buy$7.00+634.52%Maintains
4 months ago
Immunocore Holdings PLCIMCR
1Buy$84.00+53.45%Initiates Coverage On
6 months ago
Korro Bio IncKRRO
3Hold$0.50-99.25%Downgrades
7 months ago
Taysha Gene Therapies IncTSHA
4Buy$8.00+231.95%Maintains
8 months ago
Decibel Therapeutics IncDBTX
2Hold$5.25+6.92%Downgrades
8 months ago
Carisma Therapeutics IncCARM
2Buy$10.00+484.80%Reiterates
10 months ago
Vor Biopharma IncVOR
2Buy$22.00N/AMaintains
a year ago
Crispr Therapeutics AgCRSP
1Hold$46.00N/AInitiates Coverage On
a year ago
Intellia Therapeutics IncNTLA
1Hold$42.00N/AMaintains
a year ago
Allogene Therapeutics IncALLO
2Buy$12.00N/AUpgrades
a year ago
Lineage Cell Therapeutics IncLCTX
1Buy$5.00N/AInitiates Coverage On
a year ago
Renovacor IncRCOR
1Buy$9.00N/AInitiates Coverage On
2 years ago
Fate Therapeutics IncFATE
1Hold$28.00N/AInitiates Coverage On
2 years ago
Cellectis SaCLLS
2BuyN/AN/AUpgrades
2 years ago
Mink Therapeutics IncINKT
1Buy$26.00N/AInitiates Coverage On
2 years ago
Voyager Therapeutics IncVYGR
1Buy$9.00N/AUpgrades
3 years ago
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.